Personalized medicine: the impact on chemistry

An effective strategy for personalized medicine requires a major conceptual change in the development and application of therapeutics. In this article, we argue that further advances in this field should be made with reference to another conceptual shift, that of network pharmacology. We examine the intersection of personalized medicine and network pharmacology to identify strategies for the development of personalized therapies that are fully informed by network pharmacology concepts. This provides a framework for discussion of the impact personalized medicine will have on chemistry in terms of drug discovery, formulation and delivery, the adaptations and changes in ideology required and the contribution chemistry is already making. New ways of conceptualizing chemistry's relationship with medicine will lead to new approaches to drug discovery and hold the promise of delivering safer and more effective therapies.

The modern use of the term 'personalized medicine' has come to prominence over the past 10 years [1,2]. An excellent definition is to be found in the 2008 USA government report on 'Priorities for personalized medicine' [3]. It describes personalized medicines as "...*tailoring of medical treatment to the individual characteristics of each patient. It does not literally mean the creation of drugs or medical devices that are unique to a patient but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease or their response to a specific treatment. Preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and side effects for those who will not.*"

The scope of personalized medicine includes predicting individual predisposition to disease, and individualizing medical interventions once a diagnosis has been made [4]. Understanding the impact of genetic variability and acquired drug-induced effects on drug handling and effectiveness in the body are key concepts when considering the application of chemistry to personalizing medicines. Sequencing of an individual's genome has recently been shown to yield clinically useful predictive information by establishing the first protocol for querying disease-specific mutation and pharmacogenomic databases [5]. Categorizing patients into genetically definable subpopulations based on their response to a drug or disease susceptibility [6] allows physicians to tailor a particular treatment regimen to an individual's increased likelihood to respond beneficially and/or their

reduced risk of developing adverse drug reactions (ADRs). Individuals can be categorized in this way because of multiple heterogeneities with respect to genes, lifestyle and ethnicity, and co-morbidity [6]. Based on this information, a drug might be selected to have the best therapeutic outcome at the right dose for that individual [7]. The benefits accruing through personalizing medicines may become less difficult to access by understanding the complexity inherent in network pharmacology, a new and crucially important view of existing and emerging therapeutics. Network pharmacology seeks to describe therapeutically beneficial and ADR outcomes of medicines in terms of the molecular interaction of drugs with several inter-related proteins or networks. This review examines in detail the opportunities presented by the confluence of these ideas to the discoverers, formulators and prescribers of therapeutic drugs.

An ADR has been defined by Edwards and Aronson as "an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regime, or withdrawal of the product" [8]. Genetic factors are implicated in many ADRs [9]; however, development of an ADR can have other causes than the interplay of genes. These include aging, a wide range of chronic disorders, including reduced renal or hepatic function, and effects of other drug treatments to reduce the therapeutic dose requirement of some drugs. If the need for dose

**John Watkins[1],
Andrew Marsh[1],
Paul C Taylor[1] &
Donald RJ Singer[†2]**

[1]Department of Chemistry, University of Warwick, UK
[2]Clinical Pharmacology & Therapeutics, Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, UK
[†]Author for correspondence:
Tel.: +44 247 696 6097
Fax: +44 247 696 6090
E-mail: d.r.singer@warwick.ac.uk

FUTURE SCIENCE
part of **fsg**

Key terms

Adverse drug reactions: Unwanted harmful responses to medicines.

Designed multiple ligands: Single drug entity to modulate multiple targets.

Drug repurposing: Aiming to use previously approved drugs for a novel therapeutic indication.

Fixed dose combinations: Combination of two or more therapies in a single delivery system for maximum effect and adherence.

High-throughput screening: Biological screen usually in a fast, parallel format.

Network pharmacology: Seeks to describe therapeutically beneficial and adverse drug reaction outcomes of medicines in terms of the molecular interaction of drugs with several inter-related proteins or networks.

Pharmacogenomics: Study of interindividual drug response (efficacy/toxicity) based on genetic variation.

Polypharmacy: Prescription of multiple drugs.

Polypharmacology: Interaction of a small drug molecule with multiple targets.

Polypill: Combination of two or more preventative therapies in a single product.

Time-release/ sustained-release technology: Formulation of a drug that allows slow release over time.

reduction is not recognized by a prescriber, toxic levels of a drug and its metabolites may inadvertently be achieved, resulting in avoidable ADRs.

In 2004, Pirmohamed *et al.* estimated that approximately 7% of urgent admissions to hospital in the UK were caused by ADRs costing a total of GB £466 million [10]. In addition, during 2001–2002, 2.3% of patients admitted to hospital as a result of an ADR died, with 72% of these ADRs being classed as avoidable. These serious ADRs were considered largely due to individuals being prescribed multiple therapies. The term ADR has replaced both 'side effects' and 'toxic effects' to include all unwanted effects, since a side effect can include beneficial effects from a medication. There is growing interest in the value of screening for gene product variants to support personalized medicine strategy to reduce the risk of serious ADRs.

Pharmacogenomic research is yielding increasing insight into how an individual's genomic make-up affects response to a medication [11]. Knowing which targets are responsible for a disease or for adverse effects in a particular individual will better allow physicians to combat diseases by improving drug efficacy on a personalized level. Currently, clinicians still largely use the 'one-drug-fits-all' approach where the average cohort response to a treatment is taken to imply that the average person will experience these average effects [12]. There is a need to shift focus from a 'one-drug-fits-all' target approach to one where it becomes imperative to understand better how the numerous targets involved in disease and adverse or beneficial effects of treatment are inter-related.

The main class of enzymes associated with processing drugs and xenobiotics is the cytochrome P450 family (CYP450), which is found predominantly in the liver. There is a large scope for variation among individuals in activity of CYP450 enzymes. An individual's genetic makeup of this subset of enzymes has become a major area of interest for 'personalization' of drug prescription and dose. A classic early example of this variation was reported by RL Smith, who observed that a subgroup of patients taking the now superseded antihypertensive medication debrisoquine experienced a large decrease in blood pressure [13]. He reported that autosomal recessive impaired hydroxylation by the CYP2D6 drug-metabolizing enzyme in the liver was responsible. Individuals with two recessive alleles for this hydroxylating enzyme have an inherited reduced ability to metabolize debrisoquine [14]. It

is estimated that in some Caucasian populations up to 10% of individuals may have a poor metabolizing CYP2D6 genetic variant. Other clinical consequences could include reduced pain relief due to poor metabolism of the prodrug codeine to its active metabolite morphine [15] and sudden death risk cardiac arrhythmias from ECG QT prolongation with terfenadine through HERG channel activation **(Figure 1)**. CYP2D6 is now recognized to be involved in metabolizing many currently prescribed medicines. Polymorphisms of this and other CYP450 genes can confer poor, intermediate, extensive or ultra-rapid metabolizing phenotypes [16].

A similar concept now arises in clinical practice from genetic variation in activity of the purine-metabolizing enzyme thiopurine *S*-methyltransferase (TPMT), which metabolizes the thiopurine class of drugs [17] by *S*-methylation [18]. Genetic variants in the TPMT gene may lead to reduced inactivation of these drugs, which would result in accumulation of high levels of the active drug. This puts patients at risk of developing life-threatening myelosuppression [19]. Screening for TPMT activity before prescription of thiopurine drugs minimizes risk of this severe ADR [20]. The incidence of TPMT drug-metabolizing variants differs among ethnic groups [21,22].

Genes involved in processing other drugs will become easier to identify as genotyping costs decrease. Genome-wide association studies [23] will be helpful in their identification, but to reduce false-positive and false-negative results, large studies in separate well-phenotyped populations are needed, as well as better understanding of heterogeneities such as age, gender, ethnicity and co-morbidity [24]. Genome-wide association studies may also be limited [25] due to a lack of case controls [26] and inadequate understanding of the mechanisms of serious ADRs. A recent study has shown that many drugs share the same type of ADR-causing mechanism [27]. Identifying these multiple targets that are the root cause of ADRs through a 'chemical-protein interactome' [28] or extension of an archetypal protein network as illustrated in **Figure 1** would be useful both in drug development and drug use in practice. The hypothesis advanced using *in silico* work [27,28] is allied to that found through protein complementation assays [29] in that drugs sharing similar therapeutic effects through known targets frequently also share 'hidden' phenotypes, whether associated with ADRs or additional therapeutic benefit.

Figure 1. Example of a serious adverse drug reaction. ECG QT prolongation caused by the prodrug terfenadine, exacerbated by inhibition of processing by CYP2D6 or by inhibitory substances such as naringin in grapefruit juice [130]. The protein network within the large solid ellipse represents a disease-relevant network with possible link to ADR-causative protein 3 indicated by dashed line. In the particular case of terfenadine, protein 3 might be the HERG channel, which is believed to be responsible for observed ECG QT prolongation. Graphic inspired by Figure 2 in [62], modified with permission; Pioneer 10 plaque image of man used with thanks to NASA Ames Research Center [201].

A clear example of the complexity of this approach in clinical practice is achieving effective anticoagulation with the anticoagulant vitamin K antagonist warfarin [30], which is inactivated by the genetically variable enzyme CYP2C9 [31]. Patients with poor metabolizing variants of CYP2C9 have higher than expected levels of warfarin for a given dose [32]. Synthesis of coagulation factors II, VII, IX and X involves oxidation of the important co-factor vitamin K, which is then recycled to its reduced form by the enzyme vitamin K epoxide reductase (VKORC1) [33]. The maintenance dose of the drug is usually achieved by dose titration based on measurements of the time for a patient's blood to clot when the coagulation factor II (prothrombin) is added compared with a control sample (international normalized ratio). Warfarin prevents reduction of vitamin K by inhibiting VKORC1 [33]. Patients who already have a low reducing activity genetic variant of VKORC1 will have greater then expected bioactivity of warfarin [32]. It appears that genetic variation leading to increased warfarin bioactivity is present in higher frequency amongst Caucasians than Asian populations [34]. These patients are at increased risk of serious hemorrhage such as intracranial or abdominal bleeding [35]. However, if warfarin is not sufficiently clinically effective, at risk patients can develop thrombosis [36] in the heart or arteries leading, for example, to stroke [37], or in veins leading to pulmonary embolism [38]. Risks of ADRs from warfarin may be reduced if pharmacogenetic testing is undertaken. However, this is complex in clinical practice [39] as activity of these enzymes is also influenced by environmental factors that alter liver enzyme activity, such as other drugs [40] and alcohol [41]. Second, warfarin is highly protein-bound, so that a small degree of displacement of warfarin from binding sites in the bloodstream by another highly protein-bound medicine leads to a large increase in concentration of bioactive, unbound warfarin [42]. As a result of these multiple factors, genetic variability in CYP2CP and in VKORC1 appears to account for only approximately a third of the variability in clinical dosing with warfarin [43,44].

Medicinal chemists and formulation scientists of the future must be aware that in addition to genes controlling the effects of drugs, drugs may also alter gene function [7,45]. A wide range of drugs can also alter the rate of their own metabolism, by induction or inhibition of drug-metabolizing enzyme activity. A key example is rifampicin (USA: rifampin), a bactericidal antibiotic drug of the rifamycin group [46] used to treat tuberculosis and other serious infections. When rifampicin was tested in a microassay in human hepatocytes to quantify mRNA expression of drug-metabolizing enzymes [47], there was a 3.7-fold increase in mRNA for CYP2C8 and an astonishing 55-fold increase in mRNA for CYP3A4.

A further setting where personalizing medicine is important is cancer therapy, another example for which the concept of 'one drug fits all' does not hold. The dose at which to prescribe antineoplastic agents is critical, since their therapeutic window is typically narrow and the therapeutic dose range varies due to tumor heterogeneity [48]. Use of genomic technologies to optimize the right dose for the individual, would be expected to result in increased efficacy, and a reduction in ADRs, leading to improved patient adherence.

Impact on chemistry

A change in approach is required in order to advance personalized medicine, and for medicinal chemistry to have an impact on drug discovery programs in both academia and the pharmaceutical industry. Consideration of network pharmacology, contingent cellular pathways, and the use of emerging chemical biology technologies, such as chemical genomic tools, will facilitate individualized therapy to the benefit of the patient. Some of the challenges and benefits from this network approach are clear when considering clinical use of the anticancer drug trastuzumab (Herceptin®) [49]. This depended on identification of a variable treatment target: the observation that in approximately 30% of early-stage breast cancers, there is selective expression of human epidermal growth factor receptor 2 (HER2) as the major driver for tumor growth [50]. This led to a drug discovery pathway resulting in clinical development of a new biological – a monoclonal antibody – as the treatment; and parallel development of personalized diagnostics to identify the 30% of cancer patients with HER2 who could benefit from this expensive drug, based on immunohistochemistry or fluorescence *in situ* hybridization detection methods applied to cancer tissue biopsies [51].

■ Reductionism

Within chemical biology and medicinal chemistry there has been an urgency to reduce or make simpler the interactions between a small drug molecule and a single target [52], contrasting with the integrationist approach that physiologists, and more recently systems biologists, have inherently built into their research approach. Embracing this integrative approach will allow chemical biologists and medicinal chemists better understanding of complex biological systems, as required by network pharmacology. This is in contrast to designing maximally selective ligands to act on individual drug targets (**FIGURE 2**), an approach with notable successes; for example, the clinically licensed sumatriptan that provides relief from migraine by selective agonist effects on the 5-HT1D receptor subtype in temporal blood vessels [553]. However, this therapy and many others do not work in all patients with the disorder, hence the need for an individualized approach.

Figure 2. Single-target small-molecule discovery. Graphic based on Figure 3 in [59], reproduced with permission.

In essence, there has already been a key reductionist transition from pharmacogenetics to pharmacogenomics – the wealth of information from the genome allowing us to implicate multiple gene effects on disease susceptibility and drug metabolism. Genome-wide searches for candidate genes tend still to be carried out in a 'one gene, one drug and one disease' framework in line with Paul Ehrlich's 'magic bullets' theory [54], rather than drawing on fresh approaches from chemical biologists and medicinal chemists. Indeed, pharmaceutical companies are set to make their first loss in decades [55] with patents ending on highly target-selective drugs and, in addition, the subsequent decline in new selective drugs making it to effective therapies due to a lack of clinical efficacy and/or clinical safety. Clinical attrition figures therefore no longer support the current paradigm in producing drugs that are extremely selective; fewer drugs are making it to Phase II and III clinical trials [55].

■ **Network pharmacology**
Systems biology has shown us that organisms exhibit phenotypic robustness [56,57] due to cellular and organismal network complexities. Diseased states are often resistant to perturbation of a single node due to contingent mechanisms and pathways, which can result in a particular patient not responding, or becoming non-responsive to a therapy [58]. It has been shown that very selective compounds for one target may actually have a lower clinical efficacy than multitarget drugs [55]. Tackling multigenic diseases effectively, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders [59], typically require a physician to prescribe a mixture of monotherapies that, paradoxically, comprise a treatment regimen initially developed via rationale drug design to take out single targets. Serendipitously, several current drugs have been found to modulate a biological response by hitting multiple targets. For example, it appears that cardiovascular benefits from statins may result from modulation of multiple targets in addition to reducing cholesterol levels by HMG CoA reductase inhibition [52].

A network describes a series of interconnected nodes, where a node can be a gene or a gene product. As discussed in a review by Hopkins [60], a number of experiments support the case for multi-targeted therapeutics. A project to delete known genetic targets for drug metabolism in the mouse and profiling the knockouts using phenotypic assays has shown that less than 10% of the knockouts demonstrate phenotypes that may be of use toward drug target validations. In addition, single gene knockouts exhibit little or no effect on phenotype, showing the interplay of numerous genes in many processes, including drug metabolism. Only 19% of genes were found to be essential across model organisms, and from systematic genome-wide homozygous gene deletion in yeast, 15% of the knockouts result in a 'fitness defect'. Many patients often do not respond, respond minimally or adversely to a particular therapy due to the fact that many diseases are multifactorial and acting on a single node in a network under the current paradigm is not always sufficient [61,62]. Already, numerous networks/pathways have been elucidated with regards to metastatic breast cancer [63] and have allowed the identification of specific markers using a protein-network based approach.

It has been suggested that network pharmacology might also be used to rationalize why many compounds fail during later Phases of clinical trials [60]. Pharmacogenomics and pharmacogenetics can potentially describe why this may be true for certain subsets of the population; overlayed knowledge of network pharmacology will bring an understanding of how to meet this challenge. Drug repurposing [64], aiming to use previously approved drugs for novel therapeutic indications, will benefit in particular from this new view-point. These compounds have already been extensively studied and thus enter clinical practice at a much faster rate. High connectivity amongst apparently unrelated cellular processes supports the concept of drug repurposing [65].

In order to discover possible points for therapeutic intervention whilst taking account of the robustness of biological phenotypes, an interactome or network picture is needed [66]. Methods for creating this picture, and crucially, validating experimental models, link experimental and computational tools in a very direct way. In this emerging view **(FIGURE 3)**, if a protein subnet is modulated without reference to certain target(s) such as protein Z this may lead to a particular ADR, whereas co-modulation maintains network stability. Cyclooxygenase inhibitors might be an example of such a circumstance, with treatment increasing ADRs from upper-gastrointestinal bleeding through interference in the mucosal barrier, which may be protected by reducing gastric acid secretion by co-treatment with a proton pump inhibitor [67]. Selective inhibitors of COX 2 proved unexpectedly to produce a different range of

Figure 3. Examples of drugs regarded as monotherapies, mixtures of monotherapies and multi-targeted therapeutic agents [59,131]**.** The boundaries between these classifications are not always clearly defined and may change over time.

ADRs [68]. Although biochemical and prescriber knowledge has advanced, there remains unmet therapeutic need and hence medicinal chemistry opportunity as indicated in **Figure 4**.

Such a picture has also been deciphered for the B-lymphocyte to identify targets of molecular perturbations in a variety of non-Hodgkin's lymphomas from indirect expression data [69]. Networks in 'normal' cells, and those in disease states such as cancer, will be perturbed differently by therapeutics. The differential expression of CYP450 enzymes leads to additional challenges and opportunities that strengthen the case for a personalized, network-centric or multi-targeted therapeutic approach [58,65]. Thinking in the areas of polypharmacy and polypharmacology has already been helpfully linked to network pharmacology and to medicinal chemistry concepts of ligand-binding efficiency [70].

Understanding the interface between chemistry & pharmacology

Polypharmacology [71] studies the action of a single compound and its modulation of two or more molecular targets, for example the inhibition of COX isoenzymes 1 and 2 (together with other eicosanoid by nonselective nonsteroidal anti-inflammatories). This has only become apparent through the development of selective COX inhibitors. The goal of polypharmacology is not to increase or introduce promiscuity into a compound, rather to find compounds that have a biological effect by interacting with multiple targets known to play a key role in modulating the diseased state. Mapping these polypharmacological interactions will allow medicinal chemists to identify the best ways of providing multiple hits. We note that natural products have long been recognized as pleiotropic molecules that exhibit polypharmacology [72].

Polypharmacy [73] refers to the prescription of multiple, usually single drug target medications by a physician, or their use by a patient [76] (e.g., **Figure 3**). Clinicians have found current drugs typically need to be prescribed in combinations for drugs that are extremely selective for one node when multiple nodes must actually be antagonized to see therapeutic benefit when the disease is more severe; for example, in heart failure [75] and in asthma [76]. ADRs are additive as polypharmacy increases, because each additional drug has potential adverse effects and concomitant drug–drug interactions. This highlights both potential benefits and risks that may accrue with a change in drug discovery logic.

The polypill is a single pill containing a combination of active ingredients to reduce the burden of taking multiple tablets [77]. The concept

was originally created for the prophylaxis of serious cardiovascular disease, with the aim of combining a range of cardioprotective drugs in a single capsule to give maximum effect and reduce poor adherence associated with multiple separate treatments [78]. Individuals have multiple mechanisms operating within the same and different diseases. The polypill philosophy is to give 'a bit of everything' to reduce population risk of cardiovascular disease by treating the major cardiovascular risk factors: cholesterol, and diabetes and hypertension; thus protecting everyone, irrespective of genetic susceptibility to future cardiovascular problems. Whilst the polypill approach does try to take into account the variation in mechanisms among individuals within a population, and may be an attempt to personalize medicine, it does so in an impersonal fashion in that it does not take into account pharmcogenetic influences on individual constituent drugs, nor the increased potential for ADRs arising from failure to titrate dose or to personalize choice of agent.

Towards personalized multi-targeted therapeutics

Current drug design involves approaching dysregulation of a disease-causing cellular process (resulting from genetic or epigenetic changes) and antagonizing a molecular target or node central to that dysregulation. Network pharmacology aims to gain a greater understanding of dysregulation and the target(s) that are central in comparison to the healthy state, in order to uncover those to modulate for optimal therapeutic benefit **(FIGURE 5)** [79].

Personalizing these combinations based on the fact that there will be genetic variation in each of our networks and nodes might be readily accomplished. Patients with the same phenotypic disease may in fact have different altered networks that might account for differences between people in success or failure of treatment. Medicinal chemists and formulation scientists can respond by firstly taking on board these changes to drug discovery ideology and then creating, in effect, personalized 'polypills' (by altering combinations and titrating doses).

A clear justification for this multi-targeted therapeutic approach is provided by Zimmerman *et al.* [59] using an oncology analogy in relation to tumorigenic viruses, such as human papilloma viruses and hepatitis B and C. These viruses encode proteins that block the actions of the tumor suppressor genes p53 and p105Rb [80]. By inhibiting several mechanisms that usually prevent the cell from inappropriate cell cycling and proliferation, the virus essentially ensures its survival and replication. This is an evolutionarily conserved mechanism and attacking the cell on multiple fronts allows it to survive.

Figure 4. *In vivo* small-molecule discovery approach facilitated by revealing a phenotypic disease network. Solid network edges represent a subnet of therapeutic benefit; dashed lines represent a subnet leading to adverse drug reactions. Individual variability leads to differences in network nodes and edges through genetic polymorphism, deletions and copy number variants.

Figure 5. Comparison of lead molecule discovery in genetic target, mechanistic target and network target approaches.
Parentheses indicate a classic prestructure-based design approach.
PoP: proof of principle.
Modified from Figure 4 in [132] with permission.

Multiple interventions at these nodes and others will likely be key to preventing these survival or 'development of resistance' mechanisms.

There are a number of advantages and disadvantages when considering combination therapies/multi-targeted therapeutics:

- Mixture of monotherapies either as a polypill, co-formulated or prescribed separately:

  - Advantages:

    - The ratio of each monotherapy can be titrated to account for the difference in potential node potency, presence and variability amongst individuals. You can therefore tailor hypertension medication differences between the young versus old and those from black Caribbean or African descent [81]. Genetic variability may lead to large differences in the effective quantity of each drug;

    - Achieve sequenced action [82,83] at a specific target; for example, for induction-remission therapy for inflammatory disease [84] or cancer, the disease response is suppressed for the initial weeks of treatment with one strategy and then a second strategy begun once initial disease severity is contained;

- Potentially a better outcome in clinical trials (compared with multi-targeted single agent); possible cost savings, although the toxicity of the individual components must be established if not known;

- Mixture of monotherapies as a polypill improves adherence [85].

- Disadvantages:

  - Both the pharmacokinetics and phamacodynamics will need to be adjusted in a co-formulation and this may not be readily predictable. A network approach may help;

  - Trials are more complex when looking at different combinations. Blinding two treatments for prescriber and patient adds difficulty. In addition, order of administration effects need to be considered where there are mechanisms in common. For example both thiazides (T) and dihydropyridine calcium-channel blockers

(DHP) cause increased renal water and sodium excretion. When treating hypertension, the DHP nifedipine is additive to T, however T is not additive to nifedipine [86]. Problems in sequenced action might impact co-formulation in a polypill or impair patient adherence, giving scope for alternative personalizing of therapy.

- Multi-targeted single agents:
    - Advantages:
        - Regulatory approval process for companies is very attractive as it fits well within the current business model;
        - Improvements in patient adherence by taking one pill for a particular condition instead of many (although polypill and coformulation offer alternatives);
        - Sequenced action possible with a single agent through innovative chemistry, for example, selective delivery and controlled release. A cancer cell with a particular marker allows delivery of a prodrug coupled to a co-delivered activating therapeutic gene. The 'ABCD' strategy [87] pioneered at Imperial College (London, UK) for use with siRNA recognizes the problem of agent delivery; construction of an external shell around the siRNA allows it into the circulation, another protects it from liver metabolism.
    - Disadvantages:
        - Network pharmacology dictates that the drug agent must act at multiple nodes without becoming nonselective. This challenge is highlighted in the example of β-adrenoceptors that have two major subtypes relevant to current pharmaceutical treatments – β-1 which increase heart rate and force of cardiac contraction; and β-2 which relax airways and the uterus and improve blood flow to skeletal and cardiac muscle. The challenge with clinical use of β-blockers is to aim to target multiple β-adrenoceptor subtypes to ensure optimal effectiveness, while minimizing ADR incidence, for example, from low cardiac output, including heart block. For cardiovascular treatment, despite using cardioselective β-1 blockade to protect against heart attack, blockade of β-2 adrenoceptors in the lung may occur to cause the adverse effect of bronchoconstriction;
        - Using a single drug entity means it is harder to ensure multiple desired effects in people with variable functional responses to different actions;
        - Temporal or sequenced action requires innovative chemistry;
        - A single entity with sequentially evolved or designed multiple actions is likely to be a large, complex molecule, bringing problems in absorption, metabolism and excretion. A possible solution may lie in co-discovery and optimization of multiple targets, which may require a move away from current single target discovery strategies.

Designing promiscuity into a small molecule is particularly challenging. 'Designed' multiple ligands (DMLs) [55,88] have attempted to address this, but tend to be larger and more lipophilic than conventional oral therapies. These molecules have lower ligand or binding efficiency [89] (i.e., their binding energy per unit of molecular weight or lipophilicity), which impacts on potency and bioavailability of a compound. Dual ligands are generated by combining features of two selective ligands in a framework combination strategy. Success using DMLs was shown with the antipsychotic drug ziprasidone [90,91], but the combination strategy can only be used when the two selective ligands are small and they can be well integrated. This poses a significant challenge to medicinal chemists and formulation scientists and some believe that development of a clinically effective single drug entity acting on different targets in different people is almost impossible. Medicinal chemistry literature has examples of molecules with recognized dual pharmacological properties, but they may not have progressed to therapeutics for several reasons. One may observe that ligands with polypharmacology, including known toxic interactions, may eventually achieve success (see prodrug terfenadine described previously, redeveloped as fexofenadine [92]). However, in

order to fully develop ligands exhibiting dual or polypharmacology, ensuring the clinical efficacy of both, or multiple targets in combination is necessary, which may be more costly and time-consuming. Failure using DMLs was seen with the antihypertensive drug omapatrilat [93], which was designed to inhibit both neutral endopeptidase 24.11 and angiotensin converting enzyme [94] as a putative solution to treating high blood pressure and heart failure [95]. Both enzymes are involved in the breakdown of bradykinin [96]. Their dual inhibition by omapatrilat precipitated serious angio-edema due to accumulation of inflammatory peptides. Furthermore, the observed efficacy of omapatrilat was less than predicted from the effects of separate monotherapies.

This example highlights the additional concern with single multi-targeted agents that promiscuity of action will increase off-target effects, thereby increasing ADRs and thus a network pharmacology approach to drug design may be seen as counter to personalized medicine. The use of multi-targeted therapeutics may in fact enable lower doses as multiple targets are modulated, provided there is an appropriate dose for the molecule with clinical efficacy without significant toxicity for each target. Enhanced knowledge of networks within a disease state will avoid inappropriate activation that might cause ADRs. In many instances, combination therapy often has greater therapeutic selectivity than monotherapies, thus additive ADRs may not necessarily result [97].

Formulation: a joint challenge for chemists & pharmacists

Mixtures of monotherapies therefore appear promising as a pragmatic solution. As highlighted previously, the main disadvantages relate to the formulation and release of the actives and to the design of clinical trials. These challenges are not in principle insurmountable. For example, fixed-dose combination drug products [98] go some way to tackle the single monotherapy pill burden. These consist of the formulation of two or more active monotherapies combined in a single dose, for instance, the antiretroviral drug Atripla® [99] contains three drugs: efavirenz, emtricitabine and tenofovir, in one pill. Thus, chemists as well as formulation scientists will play a role in personalizing medicine in order to be able to find, harness and perfect formulations and combinations of drugs to maintain their bioavailability when combined, in addition to altering titrations of each based on a network

pharmacology analysis for perhaps different subsets of the population, based on their heterogeneities and as such individualize therapy. This may actually be far more profitable for the pharmaceutical industry in that even if patents have expired on existing drugs, they could obtain the rights to sell the fixed-dose combinations known to be of therapeutic benefit.

Time-release technology is an additional way in which formulations of drugs can be modified to allow the active ingredient to be released slowly over time [100]. Time-release gives more sustained clinical benefits and improves adherence to treatment [101]. Using a personalized medicine approach, chemists could perfect formulations for the delivery of a drug allowing steady release to be achieved. Many of these temporal-control formulations rely on the expertise of numerous chemists and other scientists – some use matrixes of insoluble substances such as acrylics and chitin [102]. Polymer-based tablets have been produced with a small exit site for the drug on one side of the tablet and a porous membrane on the other side allows stomach acid to erode the membrane, thereby delivering the drug [103]. Further exciting developments using nanostructured delivery agents [104] such as those that have been developed for several oncology therapeutics [105] continue with opportunities for input both from personalized medicine and network pharmacology agendas.

Formulation therefore becomes critical. For instance there has already been progress toward coformulated products that can be prescribed to patients for those who do not achieve adequate glycemic control with metformin [106]. Physicians can prescribe a coformulation of metformin with glyburide (Glucovance®) to increase insulin secretion from the pancreas, However, co-formulated rosiglitazone and metformin (Avandamet®) aiming to improve insulin sensitivity [107] now has only highly restricted availability. Following observation of increased cardiac events in patients treated with rosiglitazone [108,109] a 'partial clinical hold' was placed on a trial initiated by the US FDA in 2007 [110]. In response to evidence suggesting increased cardiovascular risk, the European Medicines Agency [EMA] announced in September 2010 suspension of rosiglitazone. In the USA, the FDA limited its use alone or in combination to patients with no other oral options.

Chemists need to be aware of formulation and controlled release options, alongside discovery of new monotherapies since these features are

critically important in the personalized medicine paradigm as viewed in the new landscape of network pharmacology.

Better models, assays and screening tools are thus needed to aid multitarget drug discovery. Improved *in vitro* and *in silico* models are needed to demonstrate effectiveness of combination therapy and identify optimal experimental models [66]. Current cell-free assays inadequately model biological complexity and cell-based together with whole organism phenotypic assays are certainly more appropriate. Tumor cell lines used as proliferation assays, for measuring factors such as metabolic reduction or detecting apoptosis-associated cleavage reactions, are simple examples of these, as are broader phenotypic assays such as those with multiple cell types in order to probe a wider variety of disease-relevant networks due to higher levels of systems integration [59]. *In vivo* whole organism models such as the zebrafish [111] have been used to reveal further interactions.

■ Multitarget discovery
Chemistry is responding to the need for innovative screening technologies. Classic approaches with continued value in target identification include affinity chromatography of cell lysates [112] and geneticists' forward genomic approaches [113]. More recent developments in chemical genomics [114,115] include photoimmobilization, pull-down [116] yeast two-hybrid approaches, [113] and protein complementation assays [29], have been elegantly used to link therapies to 'hidden phenotypes' of drugs.

Previously unknown interactions between small, biologically active molecules and polypeptide 'targets', have been uncovered in a phage-based chemical genomics approach, Magic Tag®, developed by researchers from the University of Warwick [117]. The method integrates phage display of polypeptides representing a proteome with photochemical immobilization of bioactives on to a surface into different orientations to maximize binding from the polypeptide library [118,119]. The technology has identified a potential interaction between β2-adrenoreceptor agonists such as salbutamol and nuclear hormone activating transcription factor 4 [117].

Although in clinical use, current therapies are far from fully understood and hence chemical genomics approaches are ideal to help rationalize the molecular targets that a drug might bind and thus build up a biochemical picture of its mode of action. Informatic approaches such as recognition of shared side-effects [120] and chemical space

descriptors of serious ADRs [121] are expanding rational network-aware approaches to the discovery of new targets and prevention of ADRs. Hence, drugs that have been rejected in late-stage clinical trials might also be examined to more fully understand reasons for observed toxicities or lack of efficacy, thereby enabling repurposing or personalized medicine approaches.

Conclusions
What is hoped for the field of personalized medicine [122] is to provide an improved diagnosis for patients, better treatment plans and modified drug-discovery programs to integrate this knowledge and to expand preventative medicine. Completion of the Human Genome Project [122] and lists of associated gene products coupled with protein maps highlighting the complexity of pathways and interactions [124–126] have allowed pharmaceutical companies to take a protein candidate from its cellular context and design highly specific drug compounds to antagonize or stimulate it. To what extent must chemists reappraise this drug discovery model?

Personalized medicine is clearly fuelling a major conceptual change within medicine. However, examples of personalized prescription of therapeutic drugs are relatively rare. The examples discussed above may highlight one of the reasons for this, since they are clear cases where variation in a single gene determines the outcome in the individual. The emerging concept of network pharmacology suggests such cases are rare and that the action of drugs is in general best understood as affecting a network. We suggest that major advances will be made when drug development programs consider not only that drugs affect individuals differently, but also that drugs interact with multiple targets in each individual. Both paradigms consider that multiple variable targets are responsible for the disease state and/or ADRs and we need to achieve a pleiotropic effect from small molecule drugs to act at these multiple, variable targets – moving away from the nonvariable, single target drug discovery approach.

The central argument of this paper is that continued adherence to a 'single-drug single-target' paradigm will limit the ability of chemists to contribute to advances in personalized medicine whether they be in discovery or delivery. The way in which network pharmacology in particular will enable change highlights the need for greater interdisciplinary overlap between chemical biology, systems biology and clinical need. This new

integrationist approach, applying the idea of networks and nodes and the variations among them to create future therapies, invites chemists to play an important role in their discovery and formulation. Implicit within this new view is the role played by educators in helping students approach these multifactorial problems.

Reductionism and the 'one-target one-gene one-disease' approach appear to have led to increased ADRs and fewer successful therapies [83] due to the lack of network pharmacology integration into the drug discovery process. An integrated network model [127] enabling chemists to chart multiple drug activities and their targets alongside undesirable off-targets [128] will advance drug development in both big and small pharmaceutical companies [129].

Future perspective

Small-molecule drugs have a bright future in personalized medicine, often in combination therapies. However, the criteria used to design and select molecules for medicinal chemistry programs may need to change to take greater account of the therapeutic delivery of the drug. Finally, the advent of tools that allow the discovery and manipulation of networks in a molecular fashion with improved prediction of individual response is likely to provide the sought-after leads.

Executive summary

- The development of personalized medicine will further expand preventative medicine and individualized therapy in clinical settings.
- Chemistry and drug discovery can adapt in a number of ways by firstly appreciating that drugs affect individuals differently in addition to the need for them to modulate multiple targets in a network pharmacology framework.
- A shift is needed from a gene-centric to a network-centric view.
- Formulation and titration by chemists of new combinations of drug molecules will be key for future personalized drug prescription.
- Novel screening technologies will aid multi-targeted drug discovery.
- There is a need for a greater interdisciplinary approach to advance personalized medicine, which includes prescribing clinicians, chemists and pharmacists formulating new combinations, and medicinal chemists designing and discovering new therapies and delivery modalities.

Bibliography

1   Bates S. Progress towards personalized medicine. *Drug Discov. Today* 15(3–4), 115–120 (2010).

2   Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. *Oncologist* 4(5), 426–427 (1999).

3   Marburger JH III, Kvamme Ef. President's Council of Advisors on Science and Technology. *Priorities for Personalized Medicine.* Office of Science Technology and Policy. Washington, DC, USA (2008).

4   Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. *Eur. J. Cancer* 40(17), 2623–2632 (2004).

5   Ashley EA, Butte AJ, Wheeler MT *et al.* Clinical assessment incorporating a personal genome. *Lancet* 375(9725), 1525–1535 (2010).

6   Bottinger EP. Foundations, promises and uncertainties of personalized medicine. *Mount Sinai J. Med.* 74(1), 15–21 (2007).

7   Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. *Hum. Mol. Genet.* 14(Spec No. 2), R207–R214 (2005).

8   Edwards Ir, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet* 356(9237), 1255–1259 (2000).

9   Kucherlapati R. Raju Kucherlapati talks about personalised medicine: breathing new life into old drugs. Interview by Steve Carney. *Drug Discov. Today* 12(7–8), 272–275 (2007).

10   Pirmohamed M, James S, Meakin S *et al.* Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ* 329(7456), 15–19 (2004).

11   Weatherall D. Royal Society Working Group on Pharmacogenetics. *Personalised medicines: hopes and realities.* Royal Society, London, UK (2005).

12   Mitri Z, Esmerian MO, Simaan JA, Sabra R, Zgheib NK. Pharmacogenetics and personalized medicine: the future for drug prescribing. *J. Med. Liban.* 58(2), 101–104 (2010).

13   Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. *Lancet* 2(8038), 584–586 (1977).

14   Hansen T, Petersen N, Iitia A, Blaabjerg O, Hyltoft-Petersen P, Horder M. Robust nonradioactive oligonucleotide ligation assay to detect a common point mutation in the CYP2D6 gene causing abnormal drug metabolism. *Clin. Chem.* 41(3), 413–418 (1995).

15   Gerd M, Johanna W. Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. *Curr. Pharmacogenomics* 3, 43–52 (2005).

16   Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J.* 5(1), 6–13 (2004).

17   Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. *Eur. J. Clin. Pharmacol.* 64(8), 753–767 (2008).

18   Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine s-methyltransferase. *Mol. Pharmacol.* 47(6), 1141–1147 (1995).

19   Yates CR, Krynetski EY, Loennechen T *et al.* Molecular diagnosis of thiopurine s *S*-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. *Ann. Intern. Med.* 126(8), 608–614 (1997).

20   Ford LT, Berg JD. Thiopurine *S*-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. *J. Clin. Pathol.* 63(4), 288–295 (2010).

21   Tai HL, Krynetski EY, Yates CR *et al.* Thiopurine *S*-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in caucasians. *Am. J. Hum. Genet.* 58(4), 694–702 (1996).

22   Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine *S*-methyltransferase gene in African–Americans. *Hum. Mol. Genet.* 8(2), 371–376 (1999).

23   Hardy J, Singleton A. Genomewide association studies and human disease. *N. Engl. J. Med.* 360(17), 1759–1768 (2009).

24   Cronin S, Tomik B, Bradley DG, Slowik A, Hardiman O. Screening for replication of genome-wide SNP associations in sporadic als. *Eur. J. Hum. Genet.* 17(2), 213–218 (2008).

25   Wang WYS, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. *Nat. Rev. Genet.* 6(2), 109–118 (2005).

26   Mccarthy MI, Abecasis GR, Cardon LR *et al.* Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat. Rev. Genet.* 9(5), 356–369 (2008).

27   Yang L, Chen J, He L. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. *PLoS Comput. Biol.* 5(7), e1000441 (2009).

28   Yang L, Luo H, Chen J, Xing Q, He L. Sepresa: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. *Nucleic Acids Res.* 37(Suppl. 2), W406–412 (2009).

29   Macdonald Ml, Lamerdin J, Owens S *et al.* Identifying off-target effects and hidden phenotypes of drugs in human cells. *Nat. Chem. Biol.* 2(6), 329–337 (2006).

30   Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. *Pharmacogenomics J.* 7(2), 99–111 (2006).

31   Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. *Blood* 96(5), 1816–1819 (2000).

32   Wadelius M, Chen LY, Downes K *et al.* Common *VKORC1* and *GGCX* polymorphisms associated with warfarin dose. *Pharmacogenomics J.* 5(4), 262–270 (2005).

33   Sconce EA, Khan TI, Wynne HA *et al.* The impact of CYP2C9 and vkorc1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. *Blood* 106(7), 2329–2333 (2005).

34   Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and vkorc1 – rationale and perspectives. *Thromb. Res.* 120(1), 1–10 (2007).

35   Landefeld CS, Ohio Lee G. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. *Am. J. Med.* 87(2), 144–152 (1989).

36   Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. *JAMA* 249(3), 374–378 (1983).

37   Mohr JP, Thompson JLP, Lazar RM *et al.* A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N. Engl. J. Med.* 345(20), 1444–1451 (2001).

38   Amstutz HC, Friscia DA, Dorey F, Carney BT. Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement. *J. of Bone Joint Surg.* 71(3), 321–326 (1989).

39   Klein TE, Altman RB, Eriksson N *et al.* Estimation of the warfarin dose with clinical and pharmacogenetic data. *N. Engl. J. Med.* 360(8), 753–764 (2009).

40   Wosilait WD, Ryan MP, Byington KH. Competition between serum albumin and soluble fraction of liver for binding of warfarin and other drugs. *Res. Commun. Chem. Pathol. Pharmacol.* 32(1), 113–121 (1981).

41   Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. *Pharmacotherapy* 25(2), 303–307 (2005).

42   Sands CD, Chan ES, Welty TE. Revisiting the significance of warfarin protein-binding displacement interactions. *Ann. Pharmacother.* 36(10), 1642–1644 (2002).

43   Lenzini P, Wadelius M, Kimmel S *et al.* Integration of genetic, clinical, and INR data to refine warfarin dosing. *Clin. Pharmacol. Ther.* 87(5), 572–578 (2010).

44   Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. *Lancet* 353(9154), 717–719 (1999).

45   Kalow W. Pharmacogenetics and personalised medicine. *Fundamen. Clin. Pharmacol.* 16(5), 337–342 (2002).

46   Nadejde C, Creanga DE, Humelnicu I, Filip E, Dorohoi DO. Study on the intermolecular interactions in rifampicin ternary solutions – calculation of microscopic parameters of rifampicin molecules. *J. Mol. Liq.* 150(1–3), 51–55 (2009).

47   Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with CDNA and oligonucleotide expression arrays. *J. Pharmacol. Exp. Ther.* 299(3), 849–857 (2001).

48   Emil F, George PC. Dose: a critical factor in cancer chemotherapy. *Am. J. Med.* 69(4), 585–594 (1980).

49   Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R. Chromogenic *in situ* hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin®) therapy. *Path. Int.* 51(8), 579–584 (2001).

50   Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. *Nat. Med.* 7(5), 548–552 (2001).

51   Sui W, Ou M, Chen J *et al.* Comparison of immunohistochemistry (IHC) and fluorescence *in situ* hybridization (FISH) assessment for her-2 status in breast cancer. *World J. Surg. Onc.* 7(1), 83 (2009).

52   Peterson RT. Chemical biology and the limits of reductionism. *Nat. Chem. Biol.* 4(11), 635–638 (2008).

53   Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in Dura Mater. *Br. J. Pharmacol.* 99(1), 202–206 (1990).

54   Kaufmann SH. Paul Ehrlich. Founder of chemotherapy. *Nat. Rev. Drug Discov.* 7(5), 373 (2008).

55   Hopkins AL. Network pharmacology: the next paradigm in drug discovery. *Nat. Chem. Biol.* 4(11), 682–690 (2008).

56   Kitano H. Biological robustness. *Nat. Rev. Genet.* 5(11), 826–837 (2004).

57   Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. *Drug Discov. Today* 12(3–4), 156–160 (2007).

58   Frantz S. Drug discovery: playing dirty. *Nature* 437(7061), 942–943 (2005).

59   Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. *Drug Discov. Today* 12(1–2), 34–42 (2007).

60   Hopkins AL. Network pharmacology. *Nat. Biotech.* 25(10), 1110–1111 (2007).

61   Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. *Trends Genet.* 15(7), 267–272 (1999).

62   Dipple KM, Mccabe ERB. Modifier genes convert 'simple' Mendelian disorders to complex traits. *Mol. Genet. Metab.* 71(1–2), 43–50 (2000).

63   Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. *Mol. Syst. Biol.* 3, 140 (2007).

64   Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. *Science* 324(5933), 1394–1395 (2009).

65   Pujol A, Mosca R, Farrés J, Aloy P. Unveiling the role of network and systems biology in drug discovery. *Trends Pharmacol. Sci.* 31(3), 115–123 (2010).

66   Pache RA, Zanzoni A, Naval J, Mas JM, Aloy P. Towards a molecular characterisation of pathological pathways. *FEBS Lett* 582(8), 1259–1265 (2008).

67   Leontiadis GI, Sreedharan A, Dorward S *et al.* Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. *Health Technol. Assess.* 11(51), 1 (2007).

68   Rovati GE, Sala A, Capra V, Dahlèn S-E, Folco G. Dual Coxib/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. *Trends Pharmacol. Sci.* 31(3), 102–107 (2010).

69   Mani KM, Lefebvre C, Wang K *et al.* A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. *Mol. Syst. Biol.* 4, 169 (2008).

70   Mestres J, Gregori-Puigjané E. Conciliating binding efficiency and polypharmacology. *Trends Pharmacol. Sci.* 30(9), 470–474 (2009).

71   Chen B, Wild D, Guha R. Pubchem as a source of polypharmacology. *J. Chem. Inf. Model.* 49(9), 2044–2055 (2009).

72   Koch MA, Schuffenhauer A, Scheck M *et al.* Charting biologically relevant chemical space: a structural classification of natural products (SCONP). *Proc. Natl Acad. Sci. USA* 102(48), 17272–17277 (2005).

73   Colley C, Lucas L. Polypharmacy. *J. Gen. Intern. Med.* 8(5), 278–283 (1993).

74   Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. *J. Am. Acad. Nurse Pract.* 17(4), 123–132 (2005).

75   Dickstein K, Cohen-Solal A, Filippatos G *et al.* ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. *Eur. Heart J.* 29(19), 2388–2442 (2008).

76   Levy ML, Thomas M, Small I, Pearce L, Pinnock H, Stephenson P. Summary of the 2008 BTS/SIGN British guideline on the management of asthma. *Prim. Care Respir. J.* 18(Suppl. 1), S1-S16 (2009).

77   Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. *BMJ* 326(7404), 1419 (2003).

78   Reddy Ks. The preventive polypill – much promise, insufficient evidence. *N. Engl. J. Med.* 356(3), 212 (2007).

79   Janga SC, Tzakos A. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. *Mol. Biosyst.* 5(12), 1536–1548 (2009).

80   Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus e7 proteins with the retinoblastoma tumor suppressor gene product. *EMBO J.* 8(13), 4099–4105 (1989).

81   Kramer H, Han C, Post W *et al.* Racial/ethnic differences in hypertension and hypertension treatment and control in the multiethnic study of atherosclerosis (MESA). *Am. J. Hypertens.* 17(10), 963–970 (2004).

82   Rösler A, Vandermeulen GWM, Klok H-A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. *Adv. Drug Deliv. Rev.* 53(1), 95–108 (2001).

83   Chung JE, Yokoyama M, Yamato M, Aoyagi T, Sakurai Y, Okano T. Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(n-isopropylacrylamide) and poly(butylmethacrylate). *J. Control. Release* 62(1–2), 115–127 (1999).

84   Mottonen T, Hannonen P, Korpela M *et al.* Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. *Arthritis Rheum.* 46(4), 894–898 (2002).

85   O'connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers. *Arch. Intern. Med.* 166(17), 1802–1804 (2006).

86   Cappuccio FP, Markandu ND, Tucker FA, Macgregor GA. Dose-response and length of action of nifedipine capsules and tablets in patients with essential-hypertension – a randomized crossover study. *Eur. J. Clin. Pharmacol.* 30(6), 723–725 (1986).

87   Kostarelos K, Miller AD. Synthetic, self-assembly abcd nanoparticles; a structural paradigm for viable synthetic nonviral vectors. *Chem. Soc. Rev.* 34(11), 970–994 (2005).

88   Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. *J. Med. Chem.* 48(21), 6523–6543 (2005).

89   Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. *Drug Discov. Today* 9(10), 430–431 (2004).

90   Nemeroff CB, Lieberman JA, Weiden PJ *et al.* From clinical research to clinical practice: a 4-year review of ziprasidone. *CNS Spectr.* 10(11) (Suppl. 17), 1–20 (2005).

91   Seeger TF, Seymour PA, Schmidt AW *et al.* Ziprasidone (cp-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. *J. Pharmacol. Exp. Ther.* 275(1), 101–113 (1995).

92   Fura A. Role of pharmacologically active metabolites in drug discovery and development. *Drug Discov. Today* 11(3–4), 133–142 (2006).

93   Andrew JSC. Omapatrilat – the story of overture and octave. *Int. J. Cardiol.* 86(1), 1–4 (2002).

94 Heudi O, Ramirez-Molina C, Marshall P *et al.* Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat. *J. Pept. Sci.* 8(11), 591–600 (2002).

95 Garcia-Robles R, Villabla F, Gonzalez-Albarran O *et al.* Effects of omapatrilat on blood pressure and the progression of renal failure in an experimental model of Type 2 diabetes mellitus. *Am. J. Hypertens.* 13(S2), 36A–36A (2000).

96 Boix F. Vasopeptidase inhibitors: a bradykinin link. *Lancet* 359(9312), 1157–1158 (2002).

97 Lehar J, Krueger AS, Avery W *et al.* Synergistic drug combinations tend to improve therapeutically relevant selectivity. *Nat. Biotech.* 27(7), 659–666 (2009).

98 Gautam CS, Saha L. Fixed dose drug combinations (FDCS): rational or irrational. A view point. *Br. J. Clin. Pharmacol.* 65(5), 795–796 (2008).

99 Herrick TM, Million RP. Tapping the potential of fixed-dose combinations. *Nat. Rev. Drug Discov.* 6(7), 513–514 (2007).

100 Hogan JE. Hydroxypropylmethylcellulose sustained release technology. *Drug Dev. Ind. Pharm.* 15(6), 975–999 (1989).

101 Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. *Diabetes, Obes. Metab.* 11(4), 338–342 (2009).

102 Heller J, Pangburn SH, Penhale DWH. Use of bioerodible polymers in self-regulated drug delivery systems. In: *Controlled-Release Technology.* American Chemical Society, Washington, DC, USA 172–187 (1987).

103 Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. *Chem. Rev.* 99(11), 3181–3198 (1999).

104 Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. *Angew. Chem. Int. Edit.* 48(5), 872–897 (2009).

105 Duncan R. Polymer conjugates as anticancer nanomedicines. *Nat. Rev. Cancer* 6(9), 688–701 (2006).

106 Moses R, Slobodniuk R, Boyages S *et al.* Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with Type 2 diabetes. *Diabetes Care* 22(1), 119–124 (1999).

107 Inzucchi SE. Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. *JAMA* 287(3), 360–372 (2002).

108 Graham DJ, Ouellet-Hellstrom R, Macurdy TE *et al.* Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. *JAMA* 304(4), 411–418 (2010).

109 Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Arch. Intern. Med.* 170(14), 1191–1201 (2010).

110 Cohen D. FDA puts rosiglitazone postmarketing trial on hold. *BMJ* 341, c4017 (2010).

111 Zon LI, Peterson RT. *In vivo* drug discovery in the zebrafish. *Nat. Rev. Drug Discov.* 4(1), 35–44 (2005).

112 Leslie BJ, Hergenrother PJ. Identification of the cellular targets of bioactive small organic molecules using affinity reagents. *Chem. Soc. Rev.* 37(7), 1347–1360 (2008).

113 Spring DR. Chemical genetics to chemical genomics: small molecules offer big insights. *Chem. Soc. Rev.* 34(6), 472–482 (2005).

114 Vegas AJ, Fuller JH, Koehler AN. Small-molecule microarrays as tools in ligand discovery. *Chem. Soc. Rev.* 37(7), 1385–1394 (2008).

115 Peddibhotla S, Dang Y, Liu JO, Romo D. Simultaneous arming and structure/activity studies of natural products employing O-H insertions: an expedient and versatile strategy for natural products-based chemical genetics. *J. Am. Chem. Soc.* 129(40), 12222–12231 (2007).

116 Kanoh N, Kumashiro S, Simizu S *et al.* Immobilization of natural products on glass slides by using a photoaffinity reaction and the detection of protein-small-molecule interactions. *Angew. Chem. Int. Ed.* 42(45), 5584–5587 (2003).

117 Ladwa SR, Dilly SJ, Clark AJ, Marsh A, Taylor PC. Rapid identification of a putative interaction between β2-adrenoreceptor agonists and ATF4 using a chemical genomics approach. *ChemMedChem* 3(5), 742–744 (2008).

118 Dilly SJ, Bell MJ, Clark AJ *et al.* A photoimmobilisation strategy that maximises exploration of chemical space in small molecule affinity selection and target discovery. *Chem. Commun. (Camb.)* (27), 2808–2810 (2007).

119 Dilly SJ, Beecham MP, Brown SP *et al.* Novel tertiary amine oxide surfaces that resist nonspecific protein adsorption. *Langmuir* 22(19), 8144–8150 (2006).

120 Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. *Science* 321(5886), 263–266 (2008).

121 Scheiber J, Jenkins JL, Sukuru SCK *et al.* Mapping adverse drug reactions in chemical space. *J. Med. Chem.* 52(9), 3103–3107 (2009).

122 Woodcock J. The prospects for 'personalized medicine' in drug development and drug therapy. *Clin. Pharmacol. Ther.* 81(2), 164–169 (2007).

123 Lander ES, Linton LM, Birren B *et al.* Initial sequencing and analysis of the human genome. *Nature* 409(6822), 860–921 (2001).

124 Rual JF, Venkatesan K, Hao T *et al.* Towards a proteome-scale map of the human protein-protein interaction network. *Nature* 437(7062), 1173–1178 (2005).

125 Stelzl U, Worm U, Lalowski M *et al.* A human protein-protein interaction network: a resource for annotating the proteome. *Cell* 122(6), 957–968 (2005).

126 Ewing RM, Chu P, Elisma F *et al.* Large-scale mapping of human protein-protein interactions by mass spectrometry. *Mol. Syst. Biol.* 3, 89 (2007).

127 Charbonnier S, Gallego O, Gavin AC. The social network of a cell: recent advances in interactome mapping. *Biotechnol. Annu. Rev.* 14, 1–28 (2008).

128 Lehar J, Stockwell BR, Giaever G, Nislow C. Combination chemical genetics. *Nat. Chem. Biol.* 4(11), 674–681 (2008).

129 Barden CJ, Weaver DF. The rise of micropharma. *Drug Discov. Today* 15(3–4), 84–87 (2010).

130 Mertens-Talcott SU, Zadezensky I, De Castro WV, Derendorf H, Butterweck V. Grapefruit-drug interactions: can interactions with drugs be avoided? *J. of Clin. Pharmacol.* 46(12), 1390–1416 (2006).

131 Corey E, Czakó B, Kürti L. *Molecules and Medicine*. Wiley, Hoboken, NJ, USA (2007).

132 Sams-Dodd F. Target-based drug discovery: is something wrong? *Drug Discov. Today* 10(2), 139–147 (2005).

■ Website

201 NASA: The Pioneer Missions. www.nasa.gov/centers/ames/missions/archive/pioneer.html (Accessed 7 September 2010)